KR20030061167A - Composition for skin whitening containing veratramine - Google Patents

Composition for skin whitening containing veratramine Download PDF

Info

Publication number
KR20030061167A
KR20030061167A KR1020020001708A KR20020001708A KR20030061167A KR 20030061167 A KR20030061167 A KR 20030061167A KR 1020020001708 A KR1020020001708 A KR 1020020001708A KR 20020001708 A KR20020001708 A KR 20020001708A KR 20030061167 A KR20030061167 A KR 20030061167A
Authority
KR
South Korea
Prior art keywords
skin
veratramine
composition
skin whitening
whitening
Prior art date
Application number
KR1020020001708A
Other languages
Korean (ko)
Other versions
KR100454736B1 (en
Inventor
진무현
김호정
김청택
김원찬
강상진
이상화
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to KR10-2002-0001708A priority Critical patent/KR100454736B1/en
Priority to AU2002359052A priority patent/AU2002359052A1/en
Priority to PCT/KR2002/002462 priority patent/WO2003057183A1/en
Publication of KR20030061167A publication Critical patent/KR20030061167A/en
Application granted granted Critical
Publication of KR100454736B1 publication Critical patent/KR100454736B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

PURPOSE: A skin whitening composition containing veratramine as an effective ingredient is provided. The composition inhibits the formation of undesired skin pigmentation by inhibiting melanin-formation and is thus effective for whitening the skin or improvement of melasma or freckles. CONSTITUTION: A skin whitening composition contains 0.000001 to 10% by weight of veratramine, based on the total weight of the composition. The veratramine is obtained by extracting roots of Veratrum nigrum or Veratrum album in a solvent such as methanol at 50 to 100deg.C for 1 to 5hr and then purifying. The composition comprises any one formulation selected from the group consisting of a skin lotion, cream, foundation, essence, gel, pack, foam cleansing, soap and ointment.

Description

베라트라민을 함유하는 피부미백용 조성물{Composition for skin whitening containing veratramine}Composition for skin whitening containing veratramine}

본 발명은 피부미백용 조성물에 관한 것으로서, 보다 상세하게는 제품 안정성이 우수하고 피부에 대한 부작용 없이 안전하게 사용될 수 있으며 멜라닌 생성을 억제하여 색소 침착 저해 효과가 뛰어난 베라트라민((3β, 23β)-14,15,16,17-tetradehydroveratramine-3,23-diol ; 이하 veratramine이라 한다)을 함유하는 피부미백용 조성물에 관한 것이다.The present invention relates to a composition for skin whitening, and more particularly, it has excellent product stability, can be safely used without side effects on the skin, and inhibits melanin production and has excellent pigmentation inhibitory effect ((3β, 23β)- It relates to a skin whitening composition containing 14,15,16,17-tetradehydroveratramine-3,23-diol (hereinafter referred to as veratramine).

희고 고운 피부를 갖고자 하는 것은 모든 사람의 한결같은 소망이다. 사람의 피부색은 피부 내부의 멜라닌(melanin) 농도와 분포에 따라 결정되는데, 유전적인 요인 외에도, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하여 도파(DOPA), 도파퀴논(dopaquinone)으로 바뀐 후 비효소적인 산화반응을 거쳐 만들어진다. 그러나, 멜라닌이 만들어지는 경로는 알려져 있지만, 티로시나제가 작용하는 이전 단계인 멜라닌 합성을 유도하는 메카니즘(mechanism)이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다.It is everyone's constant desire to have white, fair skin. Human skin color is determined by the concentration and distribution of melanin in the skin. In addition to genetic factors, it is also influenced by environmental or physiological conditions such as ultraviolet rays, fatigue and stress. Melanin is a type of amino acid tyrosine (tyrosinase) acts as an enzyme called tyrosinase (tyrosinase) is converted to dopa (DOPA), dopaquinone (dopaquinone) is produced through a non-enzymatic oxidation reaction. However, although the pathway by which melanin is made is known, it is still not clear what mechanisms induce melanin synthesis, the previous step in which tyrosinase works.

이와 같은 멜라닌의 합성이 피부 내에서 과도하게 일어나면, 피부 톤을 어둡게 하고, 기미, 주근깨 등을 발생시키기기도 한다. 따라서, 피부내의 멜라닌 색소의 합성을 저해시키면, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라 자외선, 호르몬 및 유전적인 원인에 기인하여 발생하는 기미, 주근깨 등의 피부 과색소 침착증을 개선시킬 수 있다.When such synthesis of melanin occurs excessively in the skin, it may darken the skin tone, and may cause spots and freckles. Therefore, by inhibiting the synthesis of melanin pigment in the skin, not only can brighten the skin tone to realize skin whitening, but also improve skin hyperpigmentation such as spots, freckles, etc. caused by ultraviolet rays, hormones and genetic causes. have.

따라서, 종래에는 하이드로퀴논(hydroquinone)이나 아스콜빈산(ascorbic acid), 코지산(kojic acid), 글루타티온(glutathione)과 같은 티로시나제에 대해 저해 활성을 갖는 물질을 피부외용 연고나, 에센스 등의 화장료에 배합하므로써 피부 미백을 실현하거나, 기미, 주근깨 등의 피부 과색소 침착증을 개선하였다. 그러나, 하이드로퀴논은 소정의 미백효과를 발휘하지만, 피부 자극성이 심하여 배합량을 극소량으로 제한해야 하는 문제점이 있고, 아스콜빈산은 산화되기 쉬워 이를 배합한 화장료는 변색, 변취되는 등의 문제가 발생하며, 코지산은 용액 내에서 불안전하여 화장료의 제조공정이 복잡해진다는 단점이 있다. 또한, 글루타티온, 시스테인 등의 티올계 화합물은 특유의 불쾌한 냄새를 가질 뿐만 아니라 경피흡수에도 문제점이 있고, 이들의 배당체 및 유도체들도 극성이 높으므로 화장료의 배합 성분으로 사용하기는 어렵다. 한편, 태반 추출물 등은 피부에 자극이 없으나, 미백 효과가 불충분하다.Therefore, conventionally, substances having inhibitory activity against tyrosinase such as hydroquinone, ascorbic acid, kojic acid, glutathione, and the like are applied to cosmetics such as skin ointments and essences. By blending, skin whitening was realized or skin hyperpigmentation such as blemishes and freckles was improved. However, hydroquinone exhibits a predetermined whitening effect, but has a problem of limiting the blending amount to a very small amount due to severe skin irritation. Kojic acid has the disadvantage of being unstable in solution, which complicates the manufacturing process of the cosmetic. In addition, thiol-based compounds such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have problems with transdermal absorption, and glycosides and derivatives thereof have high polarity, making it difficult to use as a cosmetic ingredient. Placenta extract, on the other hand, has no irritation to the skin, but lacks a whitening effect.

따라서, 본 발명이 이루고자 하는 기술적 과제는 상기 문제점을 해결하여 제품 안정성이 우수하고 피부에 대한 부작용 없이 안전하게 사용될 수 있을 뿐만 아니라, 멜라닌 생성을 억제하여 색소 침착 저해 효과가 뛰어난 피부미백용 조성물을 제공하는데 있다.Therefore, the technical problem to be achieved by the present invention is to solve the above problems to provide a composition for skin whitening excellent in product stability and safety can be used safely without side effects on the skin, as well as inhibiting melanin production by inhibiting pigmentation. have.

상기 기술적 과제를 달성하기 위하여, 본 발명은 베라트라민(veratramine)을 유효성분으로 함유하는 피부미백용 조성물을 제공한다.In order to achieve the above technical problem, the present invention provides a composition for skin whitening containing veratramine as an active ingredient.

본 발명에 따른 피부미백용 조성물에 있어서, 베라트라민의 함량은 조성물 총 중량을 기준으로 0.000001 내지 10중량%인 것이 바람직하다.In the composition for skin whitening according to the present invention, the content of veratramine is preferably 0.000001 to 10% by weight based on the total weight of the composition.

이하, 본 발명에 따른 피부미백용 조성물에 대하여 상세히 설명한다.Hereinafter, the composition for skin whitening according to the present invention will be described in detail.

본 발명에 따른 피부미백용 화장료에 유효성분으로 함유되는 베라트라민(veratramine)은 하기 일반식 1로 표시된다.Veraratamine (veratramine) contained in the cosmetic for skin whitening according to the present invention as an active ingredient is represented by the following general formula (1).

<일반식 1><Formula 1>

이러한 베라트라민은 항균효과(Wakan lyakugaku Zasshi, 1999, 16(5/6), 196-200)를 나타내는 것으로 보고되어 있다.These veratramines have been reported to exhibit antimicrobial effects (Wakan lyakugaku Zasshi, 1999, 16 (5/6), 196-200).

이와 같이, 베라트라민은 항균제로 알려져 있으나, 본 발명자들은 베라트라민을 이용하여 멜라닌 합성 유도 자체를 억제하는 물질까지 스크리닝(screening)할 수 있는 쥐의 멜라노마 세포(B16 mouse melanoma cell)를 대상으로 실험한 결과,이들이 매우 강력한 멜라닌 생성 억제 효과 및 미백효과를 나타냄을 밝혀냈다. 따라서, 본 발명에 따라 베라트라민을 스킨, 로션, 크림, 파운데이션, 에센스, 젤, 팩, 폼 클렌징, 비누와 같은 화장료 조성물이나 피부외용 연고와 같은 약품 조성물에 첨가하면 별다른 부작용 없이 강력한 피부 미백효과를 나타낼 수 있다.As such, veratramine is known as an antimicrobial agent, but the present inventors target a mouse melanoma cell (B16 mouse melanoma cell) capable of screening a substance that inhibits melanin synthesis induction by using veratramine. As a result, they found that they showed very strong melanin production inhibitory effect and whitening effect. Therefore, when the veratramine is added to a cosmetic composition such as skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, soap or pharmaceutical composition such as external skin ointment according to the present invention, strong skin whitening effect Can be represented.

본 발명에 따른 피부미백용 조성물의 유효성분인 베라트라민은 탄소수 27개로 이루어진 유기화합물(C27H39NO2)로서, 여로(Veratrum nigrum), 녹총(Veratrum album) 등의 뿌리에 함유되어 있는 것으로 알려져 있다. 이외에도 베라트라민은Veratrum maackii,Veratrum patulum, Eclipta alba, Veratrum taliense, Veratrum loblianum, Zygadenus sibiricus, Veratrum dahuricum, Veratrum oxysepalum, Solanum nigrum, Solanum hostmannii등으로부터 추출할 수 있다. 여로(Veratrum nigrum) 및 녹총(Veratrum album)의 뿌리로부터 베라트라민을 추출하는 방법을 예로 들면 다음과 같으나, 이에 한정하지 않는다.Veraratamine, an active ingredient of the skin whitening composition according to the present invention, is an organic compound having 27 carbon atoms (C 27 H 39 NO 2 ), which is contained in the roots of Veratrum nigrum , Veratrum album , and the like. It is known. In addition , veratramine can be extracted from Veratrum maackii , Veratrum patulum, Eclipta alba, Veratrum taliense, Veratrum loblianum, Zygadenus sibiricus, Veratrum dahuricum, Veratrum oxysepalum, Solanum nigrum, Solanum hostmannii and the like. For example, the method of extracting veratramine from the roots of Veratrum nigrum and Veratrum album is not limited thereto.

먼저, 건조된 여로(Veratrum nigrum) 또는 녹총(Veratrum album)의 뿌리를 잘게 분쇄한 후 메탄올 등의 용매로 환류냉각기가 달린 추출기에서 50~100℃로 1~5시간 가열추출한다. 이 결과물을 여과포로 여과한 후 잔사를 같은 방법으로 1회 이상 더 추출한 후, 추출액을 합하여 감압 농축한 다음 동결건조 또는 분무건조하여 건조 추출물을 얻는다. 건조 추출물을 용매 분획을 통하여 핵산 및 클로로포름 분획을 제거하고, 얻은 분획을 수포화된 부탄올로 3회 분획하여 얻은 부탄올 분획을 실리카겔, 활성 알루미나 등을 충진한 컬럼크로마토그라피와 고속액체크로마토그라피(HPLC) 등으로 정제한 다음, 분취용 HPLC 또는 재결정 방법을 이용하면 고순도의 베라트라민을 얻을 수 있다.First, finely pulverize the root of the dried furnace ( Veratrum nigrum ) or rust gun ( Veratrum album ), and then extracted by heating at 50 ~ 100 ℃ for 1-5 hours in an extractor equipped with a reflux cooler with a solvent such as methanol. The resultant was filtered with a filter cloth, and the residue was further extracted one or more times in the same manner. The extracts were combined, concentrated under reduced pressure, and lyophilized or spray dried to obtain a dry extract. The dried extract was subjected to solvent fractionation to remove the nucleic acid and chloroform fractions, and the obtained fractions were fractionated with saturated butanol three times. The butanol fractions were packed with silica gel, activated alumina, etc., column chromatography and high performance liquid chromatography (HPLC). After purification using a preparative HPLC or recrystallization method, high purity veratramine can be obtained.

또 다른 방법으로는 건조된 여로(Veratrum nigrum)의 뿌리를 클로로포름으로 추출하여 얻은 추출물에 주석산 수용액을 가하여 가용부를 NaOH로 중화시키고, 다시 클로로포름 용매분획하여 얻은 분획을 분취용 HPLC 또는 재결정 방법을 이용하면 고순도의 베라트라민을 얻을 수 있다.Another method is to add the aqueous solution of tartaric acid to the extract obtained by extracting the dried root of Veratrum nigrum with chloroform to neutralize the soluble part with NaOH, and then to separate the fraction obtained by solvent fractionation with chloroform using preparative HPLC or recrystallization. High purity veratramine can be obtained.

전술한 방법으로 얻어진 베라트라민은 피부외용연고와 같은 약품이나 화장료와 같은 다양한 피부미백용 조성물에 사용될 수 있다. 본 발명에 따른 조성물 제조시에 함유되는 베라트라민의 함량은 조성물 총중량을 기준으로 0.000001 내지 10중량%인 것이 바람직하다.Veraratamine obtained by the above-described method can be used in various skin whitening compositions such as cosmetics or cosmetics such as skin ointment. The content of veratramine contained in preparing the composition according to the present invention is preferably 0.000001 to 10% by weight based on the total weight of the composition.

이하, 본 발명을 구체적으로 설명하기 위해 실시예를 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되어져서는 안된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되어지는 것이다.Hereinafter, the present invention will be described in detail with reference to Examples. However, embodiments according to the present invention can be modified in many different forms, the scope of the present invention should not be construed as limited to the embodiments described below. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.

베라트라민 추출예Veraratamine Extraction Example

추출예 1Extraction Example 1

시판되는 건조된 여로(Veratrum nigrum)의 뿌리 1Kg를 잘게 분쇄한 후 메탄올 용매로 환류냉각기가 달린 추출기에서 3시간 동안 가열하여 추출하였다. 이 결과물을 300메쉬 여과포로 여과한 후, 잔사를 같은 방법으로 1회 이상 더 추출한후, 추출액을 합하여 감압 농축한 다음 동결건조하여 건조 추출물 52g을 얻었다. 이 건조 추출물을 용매 분획을 통하여 핵산 및 클로로포름 분획을 제거하고, 얻은 분획을 수포화된 부탄올로 3회 분획하여 얻은 부탄올 분획 24g을 실리카겔 컬럼크로마토그라피와 고속액체크로마토그라피(HPLC)로 정제한 다음, 재결정 방법을 이용하여 얻은 베라트라민을 질량분석 및 핵자기공명 스펙트럼으로 그 구조를 확인하였다.1 Kg of commercially available dried Veratrum nigrum roots were ground finely, and then extracted by heating in an extractor equipped with a reflux condenser with methanol solvent for 3 hours. The resultant was filtered through a 300 mesh filter cloth, and the residue was further extracted one or more times in the same manner. The extracts were combined, concentrated under reduced pressure, and lyophilized to obtain 52 g of dry extract. The dried extract was purified with silica gel column chromatography and high performance liquid chromatography (HPLC) after removing the nucleic acid and chloroform fractions through a solvent fraction, and fractionating the obtained fractions three times with saturated butanol. Veraratamine obtained using the recrystallization method was confirmed by mass spectrometry and nuclear magnetic resonance spectra.

추출예 2Extraction Example 2

건조된 여로(Veratrum nigrum)의 뿌리 1Kg을 클로로포름으로 추출하여 얻은 추출물 20g에 주석산 5% 수용액을 가하여 가용부를 NaOH로 중화시키고, 다시 클로로포름으로 용매분획하여 얻은 분획 1g을 재결정 방법을 이용하여 얻은 베라트라민을 질량분석 및 핵자기공명 스펙트럼으로 그 구조를 확인하였다. Veratra obtained by recrystallization method was obtained by recrystallization of 1 g of dried root of Veratrum nigrum by adding 5% aqueous solution of tartaric acid to 20 g of the extract obtained by extracting with chloroform. The structure of Min was confirmed by mass spectrometry and nuclear magnetic resonance spectra.

추출예 3Extraction Example 3

시판되는 건조된 녹총(Veratrum album)의 뿌리 1Kg를 잘게 분쇄한 후 메탄올 등의 용매로 환류냉각기가 달린 추출기에서 가열추출하였다. 이 결과물 43g을 여과포로 여과한 후 잔사를 같은 방법으로 1회 이상 더 추출한 후, 추출액을 합하여 감압 농축한 다음 동결건조 또는 분무건조하여 건조 추출물을 얻었다. 건조 추출물을 용매 분획을 통하여 핵산 및 클로로포름 분획을 제거하고, 얻은 분획을 수포화된 부탄올로 3회 분획하여 얻은 부탄올 분획 18g을 실리카겔을 충진한 컬럼크로마토그라피와 고속액체크로마토그라피(HPLC)를 통하여 베라트라민이 포함된 분획 0.4g을 얻었고, 이 분획을 분취용 HPLC 및 재결정 방법을 이용하여 얻은 베라트라민을 질량분석 및 핵자기공명 스펙트럼으로 그 구조를 확인하였다.The roots of a commercially available dried rust gun ( Veratrum album ) were pulverized finely and extracted by heating in an extractor equipped with a reflux condenser with a solvent such as methanol. 43 g of the resultant was filtered with a filter cloth, and the residue was further extracted one or more times in the same manner. The extracts were combined, concentrated under reduced pressure, and lyophilized or spray dried to obtain a dry extract. The dried extract was removed from the nucleic acid and chloroform fractions through a solvent fraction, and the obtained fractions were fractionated three times with saturated butanol. 18 g of butanol fraction was purified using silica gel-filled column chromatography and high performance liquid chromatography (HPLC). 0.4 g of a fraction containing tramin was obtained, and the structure of the veratramin obtained by preparative HPLC and recrystallization was confirmed by mass spectrometry and nuclear magnetic resonance spectra.

실험예 1~3Experimental Examples 1-3

상기 추출예에 따라 얻은 베라트라민과 알부틴 수용액을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포수준에서의 미백 효과를 실험하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). 베라트라민을 최종농도가 0.1㎍/ml, 1㎍/ml, 5㎍/ml 및 20㎍/ml가 되도록 하고(실험예 1 내지 3), 알부틴의 최종농도는 200㎍/ml로 하여 각각 B-16 멜라노마 세포의 배양배지에 첨가하여 3일간 배양한 후, 세포들을 트립신(trypsin)처리하여 배양용기로부터 떼어내 원심분리한 후 멜라닌을 추출하였다.A solution of veratramine and arbutin obtained according to the above extraction example was added to the culture solution of mouse melanoma cells (B-16 mouse melanoma cells) to test the whitening effect at the cellular level (Lotan R., Lotan D. Cancer Res 40: 3345-3350, 1980). The final concentrations of veratramine were 0.1 µg / ml, 1 µg / ml, 5 µg / ml and 20 µg / ml (Experimental Examples 1 to 3), and the final concentration of arbutin was 200 µg / ml, respectively. After incubation for 3 days by adding to -16 melanoma cells, the cells were trypsinized, separated from the culture vessel, centrifuged, and melanin was extracted.

여기에 수산화나트륨 용액(1N 농도) 1㎖를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용, 400nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 단위 세포수당(106cell) 흡광도로 나타냈다. 또한, 대조군에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하여 그 결과를 하기 표 1에 나타냈다.1 ml of sodium hydroxide solution (1N concentration) was added thereto to boil for 10 minutes to dissolve the melanin, and the absorbance was measured at 400 nm using a spectrophotometer to indicate the amount of melanin produced per unit cell count (10 6 cell). In addition, the relative melanin production relative to the control was calculated as the inhibition rate (%) and the results are shown in Table 1 below.

시료sample 멜라닌 생성량Melanin production 저해율(%)% Inhibition 대조군 (무첨가)Control group (no addition) 0.054±.0030.054 ± .003 -- 실험예 1 (최종농도 0.1㎍/ml)Experimental Example 1 (final concentration 0.1 ㎍ / ml) 0.031±.0010.031 ± .001 42%42% 실험예 2 (최종농도 1㎍/ml)Experimental Example 2 (final concentration 1 ㎍ / ml) 0.028±.0010.028 ± .001 49%49% 실험예 3 (최종농도 5㎍/ml)Experimental Example 3 (final concentration 5 ㎍ / ml) 0.016±.0010.016 ± .001 70%70% 실험예 4 (최종농도 20㎍/ml)Experimental Example 4 (final concentration 20 µg / ml) 0.006±.0010.006 ± .001 89%89% 알부틴 (최종농도 200㎍/ml)Arbutin (final concentration 200 µg / ml) 0.029±.0010.029 ± .001 47%47%

*반복수 = 3* Repeat count = 3

표 1을 참조하면, 베라트라민은 대조군과 비교할 때 배양된 쥐의 멜라노마 세포에 대하여 매우 강력한 멜라닌 생성 억제능이 있음을 알 수 있을 뿐만 아니라(실험예 1~4), 기존에 알려진 미백물질인 알부틴과 비교할 때도 그 효과가 떨어지지 않음을 알 수 있다.Referring to Table 1, veratramine was found to have a very strong melanin production inhibitory ability against melanoma cells in cultured mice compared to the control group (Experimental Examples 1 to 4), which is a known whitening substance. Compared with arbutin, the effect is not diminished.

이하에서는, 베라트라민을 피부 외용연고제, 크림, 유연화장수, 에센스, 팩 및 영양화장수에 첨가하여 피부미백용 조성물을 제조하고, 피실험자를 대상으로 이들을 처방하여 나타난 색소침착 저해효과를 살펴 본다.In the following, veratramine is added to the external skin ointment, cream, supple cosmetics, essence, pack and nutrient cosmetics to prepare a composition for skin whitening, and to examine the pigmentation inhibitory effect by prescribing them to the test subjects.

실시예 1Example 1

베라트라민을 유효성분으로 첨가하고, 하기 표 2에 기재된 성분과 함량으로 피부 외용연고제를 제조하였다.Veraratamine was added as an active ingredient, and an external skin ointment was prepared using the ingredients and contents shown in Table 2 below.

비교예 1Comparative Example 1

베라트라민을 첨가하지 않고, 하기 표 2에 기재된 성분과 함량으로 피부 외용연고제를 제조하였다.The ophthalmic ointment was prepared using the ingredients and contents shown in Table 2 without adding veratramin.

조성물Composition 실시예 1 (중량%)Example 1 (% by weight) 비교예 1 (중량%)Comparative Example 1 (% by weight) 베라트라민Veratramine 22 -- 디에틸 세바케이트Diethyl sebacate 88 88 경납Prepayment 55 55 폴리옥시에틸렌올레일에테르 포스페이트Polyoxyethylene oleyl ether phosphate 66 66 벤조산 나트륨Sodium benzoate 적량Quantity 적량Quantity 바셀린vaseline to 100to 100 to 100to 100

실시예 2Example 2

베라트라민을 유효성분으로 첨가하고, 하기 표 3에 기재된 성분과 함량으로 크림을 제조하였다.Verratamine was added as an active ingredient, and a cream was prepared using the ingredients and contents shown in Table 3 below.

비교예 2Comparative Example 2

베라트라민을 첨가하지 않고, 하기 표 3에 기재된 성분과 함량으로 크림을제조하였다.The cream was prepared with the ingredients and contents shown in Table 3 below, without the addition of veratramine.

조성물Composition 실시예 2 (중량%)Example 2 (% by weight) 비교예 2 (중량%)Comparative Example 2 (wt%) 베라트라민Veratramine 0.50.5 -- 스테아린산Stearic acid 15.015.0 15.015.0 세탄올Cetanol 1.01.0 1.01.0 수산화칼륨Potassium hydroxide 0.70.7 0.70.7 글리세린glycerin 5.05.0 5.05.0 프로필렌글리콜Propylene glycol 3.03.0 3.03.0 방부제antiseptic 적량Quantity 적량Quantity 향incense 적량Quantity 적량Quantity 정제수Purified water to 100to 100 to 100to 100

실시예 3Example 3

베라트라민을 유효성분으로 첨가하고, 하기 표 4에 기재된 성분과 함량으로 유연화장수를 제조하였다.Veraratamine was added as an active ingredient, and the softener was prepared in the ingredients and contents shown in Table 4 below.

비교예 3Comparative Example 3

베라트라민을 첨가하지 않고, 하기 표 4에 기재된 성분과 함량으로 유연화장수를 제조하였다.Softening water was prepared with the ingredients and contents shown in Table 4 below without adding veratramine.

조성물Composition 실시예 3 (중량%)Example 3 (% by weight) 비교예 3 (중량%)Comparative Example 3 (wt%) 베라트라민Veratramine 0.20.2 -- 에탄올ethanol 10.010.0 10.010.0 폴리라우린산폴리옥시에틸렌소르비탄Polylauric acid polyoxyethylene sorbitan 1.01.0 1.01.0 파라옥시안식향산메틸Methyl paraoxybenzoate 0.20.2 0.20.2 글리세린glycerin 5.05.0 5.05.0 1,3-부틸렌글리콜1,3-butylene glycol 6.06.0 6.06.0 향incense 적량Quantity 적량Quantity 색소Pigment 적량Quantity 적량Quantity 정제수Purified water to 100to 100 to 100to 100

실시예 4Example 4

베라트라민을 유효성분으로 첨가하고, 하기 표 5에 기재된 성분과 함량으로 영양화장수를 제조하였다.Veraratamine was added as an active ingredient, and nutritional longevity was prepared using the ingredients and contents shown in Table 5 below.

비교예 4Comparative Example 4

베라트라민을 첨가하지 않고, 하기 표 5에 기재된 성분과 함량으로 영양화장수를 제조하였다.No nutrient was added to the ingredients and contents shown in Table 5 below without adding veratramine.

조성물Composition 실시예 4 (중량%)Example 4 (% by weight) 비교예 4 (중량%)Comparative Example 4 (wt%) 베라트라민Veratramine 0.10.1 -- 와셀린Waselin 2.02.0 2.02.0 세스퀴올레인산소르비탄Sesquioleate sorbitan 0.80.8 0.80.8 폴리옥시에틸렌올레일에틸Polyoxyethylene oleylethyl 1.21.2 1.21.2 파라옥시안식향산메틸Methyl paraoxybenzoate 적량Quantity 적량Quantity 프로필렌글리콜Propylene glycol 5.05.0 5.05.0 에탄올ethanol 3.23.2 3.23.2 카르복시비닐폴리머Carboxy Vinyl Polymer 18.018.0 18.018.0 수산화칼륨Potassium hydroxide 0.10.1 0.10.1 색소Pigment 적량Quantity 적량Quantity 향incense 적량Quantity 적량Quantity 정제수Purified water to 100to 100 to 100to 100

실시예 5Example 5

베라트라민을 유효성분으로 첨가하고, 하기 표 6에 기재된 성분과 함량으로 팩을 제조하였다.Verratamine was added as an active ingredient, and a pack was prepared with the ingredients and contents shown in Table 6 below.

비교예 5Comparative Example 5

베라트라민을 첨가하지 않고, 하기 표 6에 기재된 성분과 함량으로 팩을 제조하였다.Packs were prepared with the ingredients and contents shown in Table 6 below, without the addition of verratamine.

조성물Composition 실시예 5 (중량%)Example 5 (% by weight) 비교예 5 (중량%)Comparative Example 5 (wt%) 베라트라민Veratramine 0.20.2 -- 글리세린glycerin 5.05.0 5.05.0 프로필렌글리콜Propylene glycol 4.04.0 4.04.0 폴리비닐알코올Polyvinyl alcohol 15.015.0 15.015.0 에탄올ethanol 8.08.0 8.08.0 폴리옥시에틸렌올레일에틸Polyoxyethylene oleylethyl 1.01.0 1.01.0 파라옥시안식향산메틸Methyl paraoxybenzoate 0.20.2 0.20.2 향incense 적량Quantity 적량Quantity 색소Pigment 적량Quantity 적량Quantity 정제수Purified water to 100to 100 to 100to 100

실시예 6Example 6

베라트라민을 유효성분으로 첨가하고, 하기 표 7에 기재된 성분과 함량으로 에센스를 제조하였다.Veraratamine was added as an active ingredient, and an essence was prepared with the ingredients and contents shown in Table 7 below.

비교예 6Comparative Example 6

베라트라민을 첨가하지 않고, 하기 표 7에 기재된 성분과 함량으로 에센스를 제조하였다.Essence was prepared with the ingredients and contents shown in Table 7 below, without the addition of beratramine.

조성물Composition 실시예 6 (중량%)Example 6 (% by weight) 비교예 6 (중량%)Comparative Example 6 (wt%) 베라트라민Veratramine 1.01.0 -- 프로필렌글리콜Propylene glycol 10.010.0 10.010.0 글리세린glycerin 10.010.0 10.010.0 히알루론산나트륨수용액(1%)Sodium hyaluronate aqueous solution (1%) 5.05.0 5.05.0 에탄올ethanol 5.05.0 5.05.0 폴리옥시에틸렌경화피마자유Polyoxyethylene Cured Castor Oil 1.01.0 1.01.0 파라옥시안식향산메틸Methyl paraoxybenzoate 0.10.1 0.10.1 향incense 적량Quantity 적량Quantity 정제수Purified water to 100to 100 to 100to 100

전술한 바와 같이 제조한 피부 외용연고제, 크림, 유연화장수, 영양화장수, 팩, 에센스에 의한 색소 침착 저해 효과를 검증하기 위해 사용한 방법은 다음과 같다.The method used to verify the pigmentation inhibitory effect by the skin external ointment, cream, supple cosmetics, nutrient cosmetics, pack, essence prepared as described above is as follows.

먼저, 건강한 남녀 20명씩을 선정하여 양팔의 하박부에 직경 7㎜ 크기의 구멍이 6개씩 2줄로 파인 알루미늄 호일을 붙이고, 팔에서 10㎝ 떨어진 거리에서 ORIEL solar simulaltor 1000W를 사용하여 60mJ/㎠의 광량을 조사하였다. 조사전에 70% 에탄올 수용액으로 조사부위를 잘 세척하였다. 조사하기 3일전부터 조사후 3주째까지 1일 2회씩 실시예 1 내지 6에 따라 제조된 베라트라민 함유 조성물과, 비교예 1 내지 6에 따라 베라트라민이 함유되지 않은 기제를 한 쌍으로 같은 줄에 도포하였다. 여기서, 실시예 5 및 비교예 5의 팩제는 도포한 다음 15분 후에 떼어냈다.First, select 20 healthy men and women and attach aluminum foil with two rows of 6 holes with a diameter of 7 mm in the lower part of both arms. Was investigated. The irradiation site was washed well with 70% ethanol aqueous solution before irradiation. Veramin-containing composition prepared according to Examples 1 to 6 twice a day from 3 days before irradiation to 3 weeks after irradiation, and the same row in pairs of the base without Veratramin according to Comparative Examples 1 to 6 Was applied. Here, the pack agents of Example 5 and Comparative Example 5 were removed 15 minutes after the application.

상기 방법에 따라 각각의 실시예와 비교예에 따른 조성물을 처방한 후, 색소침착도를 육안으로 판정하고, 각 실시예에 따른 조성물과 비교예에 따른 조성물의 색소침착 억제 정도를 비교하여 효과 있음, 차이 없음의 2단계로 평가하고, 아울러 피부 부작용 발생여부를 조사하여 그 결과를 하기 표 8에 나타냈다.After prescribing a composition according to each example and a comparative example according to the above method, the degree of pigmentation was visually determined, and the pigmentation inhibition degree of the composition according to each example and the composition according to the comparative example was effective. , And evaluated in two stages of no difference, and also examined the occurrence of skin side effects are shown in Table 8 below.

실험물질Experimental substance 효과있음(명)Effective (persons) 차이없음(명)No difference (persons) 부작용(명)Side effects (persons) 실시예 1Example 1 1717 33 00 실시예 2Example 2 1414 66 00 실시예 3Example 3 1414 66 00 실시예 4Example 4 1313 77 00 실시예 5Example 5 1414 66 00 실시예 6Example 6 1515 55 00

상기 표 8에 나타난 바와 같이, 실시예 1 내지 6에 따라 제조된 베라트라민 함유 조성물은 피시험자 20명중 최소 13명 이상에 대하여 상당한 피부 미백효과를 나타내었으며, 피부내에 어떤 부작용도 나타나지 않았음을 알 수 있었다.As shown in Table 8, the veratramine-containing compositions prepared according to Examples 1 to 6 exhibited significant skin whitening effects on at least 13 of 20 subjects, and did not show any side effects in the skin. Could know.

이와 같이 본 발명에 따른 베라트라민을 함유하는 피부미백용 조성물은 멜라닌 생성을 억제하여 색소 침착을 저해하므로, 피부미백 또는 기미나 주근깨 개선에 효과적이다. 또한, 피부내에 어떤 부작용도 나타나지 않으므로 안전하게 사용될 수 있다.As described above, the composition for skin whitening containing veratramine according to the present invention inhibits melanin production and inhibits pigmentation, and thus is effective for improving skin whitening or freckles and freckles. It can also be used safely because it does not show any side effects in the skin.

Claims (3)

하기 일반식 1로 표시되는 베라트라민(veratramine)을 유효성분으로 함유하는 것을 특징으로 하는 피부미백용 조성물.A skin whitening composition comprising veratramine represented by the following general formula 1 as an active ingredient. <일반식 1><Formula 1> 제1항에 있어서, 상기 베라트라민의 함량은 조성물 총 중량을 기준으로 0.000001 내지 10중량%인 것을 특징으로 하는 피부미백용 조성물.According to claim 1, wherein the content of the veratramine is a composition for skin whitening, characterized in that 0.000001 to 10% by weight based on the total weight of the composition. 제1항에 있어서, 상기 피부미백용 조성물은 스킨, 로션, 크림, 파운데이션, 에센스, 젤, 팩, 폼 클렌징, 비누 및 피부외용 연고로 이루어진 군으로부터 선택된 어느 하나의 제형으로 이루어진 것을 특징으로 하는 피부미백용 조성물.According to claim 1, wherein the skin whitening composition is a skin whitening, characterized in that consisting of any one selected from the group consisting of skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, soap and skin ointment. Composition.
KR10-2002-0001708A 2002-01-11 2002-01-11 Composition for skin whitening containing veratramine KR100454736B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR10-2002-0001708A KR100454736B1 (en) 2002-01-11 2002-01-11 Composition for skin whitening containing veratramine
AU2002359052A AU2002359052A1 (en) 2002-01-11 2002-12-27 Composition for skin whitening
PCT/KR2002/002462 WO2003057183A1 (en) 2002-01-11 2002-12-27 Composition for skin whitening

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2002-0001708A KR100454736B1 (en) 2002-01-11 2002-01-11 Composition for skin whitening containing veratramine

Publications (2)

Publication Number Publication Date
KR20030061167A true KR20030061167A (en) 2003-07-18
KR100454736B1 KR100454736B1 (en) 2004-11-05

Family

ID=19718400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-0001708A KR100454736B1 (en) 2002-01-11 2002-01-11 Composition for skin whitening containing veratramine

Country Status (3)

Country Link
KR (1) KR100454736B1 (en)
AU (1) AU2002359052A1 (en)
WO (1) WO2003057183A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100713857B1 (en) * 2005-12-05 2007-05-10 한국생명공학연구원 Fungicides compositions comprising the extract of veratrum japonicum and veratramine isolated from them
KR100790562B1 (en) * 2006-12-07 2008-01-03 삼성에버랜드 주식회사 Compositions for treatment of turf disease containing extracts from veratrum oxysepalum turcz and lycoris flavescens m.y.kim and s.t.lee and methods of production thereof
KR20150081967A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising 3,23-Diacetyl-N-methylveratramine
KR20150081966A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising triacetylveratramine
KR20150081965A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising N-Methylveratramine
KR20200037183A (en) * 2020-03-31 2020-04-08 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising N-Methylveratramine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011256135A (en) * 2010-06-09 2011-12-22 Kao Corp Dopa oxidase activity inhibitor, bleaching agent and external preparation for skin, and extract of veratrum nigrum l. usable therefor
CN103520431A (en) * 2012-07-04 2014-01-22 江苏天晟药业有限公司 Preparation method of veratrum alkaloid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005241A (en) * 1995-07-26 1997-02-19 장택희 Electronic stethoscope
KR100797367B1 (en) * 2000-10-12 2008-01-22 주식회사 엘지생활건강 Cosmetic composition containing Veratrum nigrum L. extracts
KR100757130B1 (en) * 2001-07-11 2007-09-10 주식회사 엘지생활건강 Cosmetic for skin whitening containing verazine and epi-verazine with inhibitory activity of melanin formation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100713857B1 (en) * 2005-12-05 2007-05-10 한국생명공학연구원 Fungicides compositions comprising the extract of veratrum japonicum and veratramine isolated from them
KR100790562B1 (en) * 2006-12-07 2008-01-03 삼성에버랜드 주식회사 Compositions for treatment of turf disease containing extracts from veratrum oxysepalum turcz and lycoris flavescens m.y.kim and s.t.lee and methods of production thereof
KR20150081967A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising 3,23-Diacetyl-N-methylveratramine
KR20150081966A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising triacetylveratramine
KR20150081965A (en) * 2014-01-07 2015-07-15 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising N-Methylveratramine
KR20200037183A (en) * 2020-03-31 2020-04-08 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation, and skin whitening comprising N-Methylveratramine

Also Published As

Publication number Publication date
WO2003057183A1 (en) 2003-07-17
AU2002359052A1 (en) 2003-07-24
KR100454736B1 (en) 2004-11-05

Similar Documents

Publication Publication Date Title
KR100777554B1 (en) Composition for skin whitening containing Sitosterol
JPH07187989A (en) Extracted solution of perilla frutescens and skin-beautifying cosmetic containing the same
KR100454736B1 (en) Composition for skin whitening containing veratramine
KR100757130B1 (en) Cosmetic for skin whitening containing verazine and epi-verazine with inhibitory activity of melanin formation
KR100190992B1 (en) A skin whitening composition containing extracts of asparagus cochinchinensis and tyrosinase inhibitor
KR20050092313A (en) Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation
KR100509848B1 (en) Composition for skin whitening
KR100789632B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR100789634B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR100431271B1 (en) Composition for skin whitening containing Arecoline
KR20020029182A (en) Cosmetic composition containing Veratrum nigrum L. extracts and Potentilla chinensis Ser. extracts
KR100789635B1 (en) Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation
KR100453217B1 (en) Skin whitener
KR20050092314A (en) Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation
KR100770124B1 (en) Composition for skin whitening containing machilin-A
KR20040059005A (en) Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation
KR100777589B1 (en) Composition for skin whitening containing Physalindicanol-A
KR100789631B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR100724168B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR20040059007A (en) Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation
KR20020029184A (en) Cosmetic composition containing Acalypha australis L. extracts and Pterocarya stenoptera DC extracts
CN100352825C (en) Extractive form active ingredient of bitter bamboo, prepartion method and application
KR20040059006A (en) Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation
KR100789633B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR20030037993A (en) Composition for skin whitening containing 1-desgalloyleugeniin

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080910

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee